Previous close | 0.0000 |
Open | 0.0500 |
Bid | 0.0000 |
Ask | 5.0000 |
Strike | 2.50 |
Expiry date | 2024-08-16 |
Day's range | 0.0500 - 0.0500 |
Contract range | N/A |
Volume | |
Open interest | N/A |
Cyclacel Pharmaceuticals (CYCC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- Novel CDK2/9 inhibitor fadraciclib induces anaphase catastrophe, a novel cancer-specific mechanism of action - BERKELEY HEIGHTS, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced a presentation by independent investigators of preclinical data demonstrating therapeutic potential of fadraciclib, the Company’s cy
- Clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing proof of concept study in patients with solid tumors and lymphoma - BERKELEY HEIGHTS, N.J., June 03, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that new clinical, pharmacokinetic (PK) and pharmacodynamic (PD) data from